Mylan NV (MYL)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

1500 CORPORATE DRIVE CANONSBURG, PA 15317

Mylan is engaged in the development, licensing, manufacture, marketing and distribution of generic and branded generic pharmaceuticals, pharmaceuticals line and active pharmaceutical ingredients. Co. has two reportable segments: Generics, which develops, manufactures, sells, and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as active pharmaceutical ingredients: and Specialty, which manufactures and sales branded specialty nebulized and injectable products. The Generics segment also focuses on developing active pharmaceutical ingredients with non-infringing processes.

Data as of 2020-09-12
Market Cap7.925 Billion Shares Outstanding516.947 Million Avg 30-day Volume5.191 Million
P/E Ratio28.4 Dividend Yield EPS0.53
Price/Sales0.689 Price cash flow ratio4.2 Price free cash flow ratio6.1
Book Value22.72 Price to Tangible Book-0.89 Alpha-0.03
Short Interest Ratio % Short Interest to Float R-squared0.403959
BETA1.50429 52-week High/Low23.11 / 12.75 Stddev0.101128
View SEC Filings from MYL instead.
Q2 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 12 12 0.0% 10 (0.65%) 9 (0.58%) 11.11%
Funds Holding: 430 441 -2.49% 91 (5.94%) 97 (6.2%) -6.19%
13F shares: 456.365 Million 442.843 Million 3.05% 178.492 Million 170.082 Million 4.94%
% Ownership 88.2809 85.7929 2.9% 34.5281 32.9503 4.79%
New Positions: 58 71 -18.31% 15 22 -31.82%
Increased Positions 173 139 24.46% 46 26 76.92%
Closed Positions 63 90 -30.0% 18 36 -50.0%
Reduced Positions 123 149 -17.45% 20 41 -51.22%
Total Calls 8.232 Million 10.592 Million -22.28% 2.325 Million 3.177 Million -26.81%
Total Puts 19.751 Million 18.754 Million 5.32% 10.774 Million 10.1 Million 6.67%
PUT/CALL Ratio 2.4 1.77 35.59% 4.63 3.18 45.6%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding MYL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MYL BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

12.5 Thousand total shares from 1 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

PARRISH MARK W

  • Director
58,295 2020-08-11 2

BRESCH HEATHER M CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
581,799 2020-03-02 1

VANDERVEEN RANDALL L

  • Director
47,787 2020-03-02 1

MAURO ANTHONY CHIEF COMMERCIAL OFFICER

  • Officer
124,879 2020-03-02 1

KORMAN HARRY

  • Director
26,515 2020-03-02 1

MALIK RAJIV PRESIDENT

  • Officer
  • Director
548,064 2020-03-02 1

CINDRICH ROBERT J

  • Director
25,725 2020-03-02 1

DIMICK NEIL F

  • Director
51,263 2020-03-02 1

HIGGINS MELINA E

  • Director
113,131 2020-03-02 1

LYONS DILLON JOELLEN

  • Director
15,609 2020-03-02 1

CAMPBELL PAUL SEE REMARKS

  • Officer
31,162 2020-03-02 2

PARKS KENNETH SCOTT CHIEF FINANCIAL OFFICER

  • Officer
35,115 2020-03-02 1

VOLLEBREGT SJOERD S

  • Director
48,269 2020-03-02 1

VAN DER MEER MOHR PAULINE

  • Director
6,265 2020-03-02 1

MARK RICHARD A

  • Director
9,228 2020-03-02 1

COURY ROBERT J

  • Director
1,383,587 2019-08-02 0

GALLAGHER DANIEL MARTIN JR CHIEF LEGAL OFFICER

  • Officer
17,041 2019-04-01 0

BRESCH HEATHER M CHIEF EXECUTIVE OFFICER

BRESCH HEATHER M CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
618,230 2019-03-01 1

CAMERON WENDY

  • Director
No longer subject to file 2018-06-29 0

PIATT RODNEY L

  • Director
No longer subject to file 2017-06-22 0

LEECH DOUGLAS J

  • Director
No longer subject to file 2017-06-22 0

MAROON JOSEPH C MD

  • Director
No longer subject to file 2017-06-22 0

ABBOTT LABORATORIES

ABBOTT PRODUCTS

ABBOTT INVESTMENTS LUXEMBOURG S.A R.L.

  • 10% Owner
No longer subject to file 2017-03-23 0

SHEEHAN JOHN D EVP AND CFO

  • Officer
193,732 2016-03-24 0

ABBOTT PRODUCTS

  • 10% Owner
62,782,018 2015-07-28 0

ABBOTT LABORATORIES

ABBOTT ESTABLISHED PRODUCTS HOLDINGS GIBRALTAR LTD

ABBOTT INVESTMENTS LUXEMBOURG S.A R.L.

  • 10% Owner
69,750,000 2015-04-07 0

ABBOTT LABORATORIES

LABORATOIRES FOURNIER S.A.S.

ABBOTT ESTABLISHED PRODUCTS HOLDINGS GIBRALTAR LTD

ABBOTT INVESTMENTS LUXEMBOURG S.A R.L.

  • 10% Owner
75,000,000 2015-03-31 0

TODD C B

  • Director
229,636 2014-03-14 0

RIZZO DANIEL C JR SVP, CORP CONTROLLER & CAO

  • Officer
83,140 2014-03-06 0

VARNEY JOLENE L. CHIEF FINANCIAL OFFICER

  • Officer
0 2009-06-08 0

PUSKAR MIKE

  • Director
0 2009-05-07 0

NIMMAGADDA PRASAD

  • Director
1,205,308 2009-04-25 0

BORKOWSKI EDWARD CHIEF FINANCIAL OFFICER

  • Officer
78,300 2009-03-18 0

WILLIAMS STUART A SPECIAL COUNSEL, OFFICE OF CEO

  • Officer
110,433 2008-03-07 0

MYERS CAROLYN J PRESIDENT, DEY L.P.

  • Officer
8,507 2008-02-14 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

PARRISH MARK W - Director

2020-08-12 18:02:07 -0400 2020-08-11 P 12,500 $16.79 a 58,295 direct 0.3098 1.2392 2.2924 5 0.0 1

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments